HK1029599A1 - Methods and compositions for cancer therapies using genes encoding interferon-beta - Google Patents

Methods and compositions for cancer therapies using genes encoding interferon-beta

Info

Publication number
HK1029599A1
HK1029599A1 HK00107877A HK00107877A HK1029599A1 HK 1029599 A1 HK1029599 A1 HK 1029599A1 HK 00107877 A HK00107877 A HK 00107877A HK 00107877 A HK00107877 A HK 00107877A HK 1029599 A1 HK1029599 A1 HK 1029599A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
beta
genes encoding
cancer therapies
Prior art date
Application number
HK00107877A
Other languages
English (en)
Inventor
James G Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1029599A1 publication Critical patent/HK1029599A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK00107877A 1997-08-29 2000-12-07 Methods and compositions for cancer therapies using genes encoding interferon-beta HK1029599A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (1)

Publication Number Publication Date
HK1029599A1 true HK1029599A1 (en) 2001-04-06

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00107877A HK1029599A1 (en) 1997-08-29 2000-12-07 Methods and compositions for cancer therapies using genes encoding interferon-beta

Country Status (25)

Country Link
EP (1) EP1007717B8 (is)
JP (3) JP4124565B2 (is)
KR (1) KR100699285B1 (is)
CN (1) CN100342019C (is)
AT (1) ATE316145T1 (is)
AU (1) AU740428B2 (is)
BR (1) BR9812138A (is)
CA (1) CA2300480C (is)
CY (1) CY1105029T1 (is)
CZ (2) CZ297314B6 (is)
DE (1) DE69833264T2 (is)
DK (1) DK1007717T3 (is)
EA (1) EA003256B1 (is)
EE (1) EE04873B1 (is)
ES (1) ES2257817T3 (is)
HK (1) HK1029599A1 (is)
HU (1) HU224422B1 (is)
IL (2) IL134593A0 (is)
IS (1) IS2318B (is)
NO (1) NO20000990L (is)
NZ (1) NZ503401A (is)
PT (1) PT1007717E (is)
SK (1) SK286821B6 (is)
TR (1) TR200000532T2 (is)
WO (1) WO1999010516A2 (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
KR20220025757A (ko) * 2019-06-01 2022-03-03 시벡 바이오테크놀로지스, 엘엘씨 진핵 세포에 유전자 편집 시스템을 전달하기 위한 박테리아 플랫폼

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP0707071B1 (en) * 1994-08-16 2003-07-30 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
SK286821B6 (sk) 2009-06-05
JP2005225888A (ja) 2005-08-25
TR200000532T2 (tr) 2000-11-21
SK2482000A3 (en) 2000-08-14
AU740428B2 (en) 2001-11-01
BR9812138A (pt) 2000-07-18
DK1007717T3 (da) 2006-05-29
IL134593A (en) 2007-06-17
EA003256B1 (ru) 2003-02-27
EE04873B1 (et) 2007-08-15
IS2318B (is) 2007-11-15
WO1999010516A3 (en) 1999-05-06
EP1007717A2 (en) 2000-06-14
DE69833264D1 (de) 2006-04-06
HUP0002913A2 (hu) 2000-12-28
HUP0002913A3 (en) 2003-08-28
EE200000102A (et) 2000-12-15
NZ503401A (en) 2003-01-31
CN100342019C (zh) 2007-10-10
CZ299095B6 (cs) 2008-04-23
CA2300480A1 (en) 1999-03-04
AU9205198A (en) 1999-03-16
JP2004155786A (ja) 2004-06-03
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
PT1007717E (pt) 2006-06-30
HU224422B1 (hu) 2005-08-29
EP1007717B8 (en) 2006-05-03
JP2001514010A (ja) 2001-09-11
NO20000990D0 (no) 2000-02-28
KR20010023511A (ko) 2001-03-26
CA2300480C (en) 2010-01-05
IS5374A (is) 2000-02-11
WO1999010516A2 (en) 1999-03-04
CZ2000733A3 (cs) 2000-06-14
JP4219335B2 (ja) 2009-02-04
NO20000990L (no) 2000-05-02
ATE316145T1 (de) 2006-02-15
CN1271391A (zh) 2000-10-25
EA200000270A1 (ru) 2000-10-30
JP4124565B2 (ja) 2008-07-23
CZ297314B6 (cs) 2006-11-15
DE69833264T2 (de) 2006-09-28
ES2257817T3 (es) 2006-08-01
CY1105029T1 (el) 2010-03-03
JP3953458B2 (ja) 2007-08-08
KR100699285B1 (ko) 2007-03-26

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
EP1024197A3 (en) Mesothelial cell gene therapy
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
WO1997030731A3 (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IL141984A0 (en) Akt nucleic acids, polypeptides, and uses thereof
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
ZA961161B (en) Medicinal combination for transfecting and expressing exogenous genes in vivo
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
WO2000006735A8 (en) Interferon alpha hybrids
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120825